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Introduction
Antibody-cytokine fusions (also called "immunocytokines") represent an emerging class of engineered cytokine products, that may display a superior anti-cancer activity as a consequence of a preferential accumulation at the tumor site, helping spare normal organs (1) . An increased density of lymphocyte within the tumor mass typically correlates with a better prognosis, both in mice and in cancer patients (2) (3) (4) (5) . The targeted delivery of cytokines to the tumor environment may increase the intratumoral density of T-cells and NK cell (2, 4, 6) . In this context, IL2 and interleukin-12 (IL12) have proven to be particularly attractive payloads for antibody-based delivery applications (7) (8) (9) , as these agents can potently activate T-cells and NK cells.
Antibody-cytokine fusions with tumor-homing properties are likely to display their therapeutic action and to increase the therapeutic index of the corresponding cytokine payload as a result of a specific activation and proliferation of tumor-resident CD8+ T cells and of NK cells, which recognize malignant structures (2, 3) . For some pro-inflammatory cytokine payload (e.g., IL12), it has been shown that an antibody-based targeted delivery to the tumor may increase therapeutic activity by at least 20-fold, compared to the recombinant cytokine counterpart (10) .
Antibody-cytokine fusion proteins in clinical trials for the treatment of cancer include various antibody-IL2 fusions (e.g., hu14.18-IL2 (11) , huKS-IL2 (12), L19-IL2 (13), F16-IL2 (14) , CEA-IL2v (15) , NHS-IL2 (16), DI-Leu16-IL2 (17)), as well as fusions with TNF (e.g., L19-TNF (18) ) and with IL12 (BC1-IL12 (19) and NHS-IL12 (20) ). More recently, scientists at Glycart-Roche have described a novel antibody fusion with human 4-1BBL, which has started clinical trials (21) . The most advanced product may be represented by a combination of L19-IL2 with L19-TNF, which is currently being investigated in Phase III clinical trials (EudraCT number: 2015-002549-72 and NCT03567889) for the treatment of fully-resectable Stage IIIB,C melanoma (22) . IL2 and TNF are representative examples of cytokines which work well when used in combination. Our group already described in 2010 that the simultaneous administration of L19-IL2 and L19-TNF in an immunocompetent mouse model of neuroblastoma was more active than the products given as single agents. Indeed, the combined use of the two products cured the majority of mice (23) . A synergistic benefit for L19-IL2 and L19-TNF was also observed for intralesional administration procedures in mouse models of cancer (24) . This work paved the way for the execution of a Phase II clinical trial in melanoma patients (22) , which has then triggered Phase III study programs in Europe and in the United States. Tumor necrosis factor and IL2 are synergistic and complementary also from a pharmacodynamic viewpoint. TNF damages the tumor endothelium leading to a rapid hemorrhagic necrosis of the neoplastic mass (4, 6, 25) , while IL2 mainly acts by activating NK cells and CD8+ lymphocytes (6, 24, 26) .
The synergistic action of IL2 and TNF has stimulated research activities, aimed at incorporating both payloads into the same therapeutic product. We have previously described the production and anti-cancer activity of a dual-cytokine fusion protein (termed IL2-F8-TNF mut ), which exhibited a selective accumulation at the tumor site following intravenous administration and a potent anti-cancer activity, particularly against murine soft-tissue sarcomas (6) . The therapeutic action of IL2-F8-TNF mut could be potentiated by combination with immune checkpoint inhibitors (27) .
Here, were report the cloning, production and characterization (in vitro and in vivo) of a novel fusion protein (termed IL2-XE114-TNF mut ), capable of recognizing carbonic anhydrase IX (CAIX) and of simultaneously displaying IL2 and a de-potentiated TNF mutant (TNF mut ).
CAIX is a membrane protein, which is overexpressed in hypoxia conditions and in various cancer types, including renal cell carcinomas (RCC), urothelial, colorectal, stomach, pancreas and other cancers (28, 29) . This antigen is virtually undetectable in most normal adult tissues, exception made for certain gastrointestinal structures (29) . CAIX has been targeted in vivo using both antibody-and small molecule-based products, showing interesting results in imaging studies (30) (31) (32) .
The product was active in vitro and in vivo and may represent a candidate for the immunotherapy of renal cell carcinoma.
Materials and Methods

Tumor cell lines
The human renal cell carcinoma cell line SKRC52 was kindly provided by Professor E.
Oosterwijk (Radbound University Nijmegen Medical Centre, Nijmegen, the Netherlands).
Transfected CT26-CAIX cells were prepared as previously reported (30) . CHO cells, CTLL2 cells and L-M fibroblasts were obtained from the ATCC. Cell lines were received between 2017 and 2019, expanded, and stored as cryopreserved aliquots in liquid nitrogen. Cells were grown according the supplier's protocol and kept in culture for no longer than 14 passages.
Authentication of the cell lines also including check of postfreeze viability, growth properties, and morphology, test for mycoplasma contamination, isoenzyme assay, and sterility test were performed by the cell bank before shipment.
Mice and tumor models
Six to eight-week-old female BALB/c nude mice were obtained from Janvier Labs. Tumor cells were implanted subcutaneously in the flank using 1x10 7 cells (SKRC52), 3x10 6 cells (CT26-CAIX). Experiments were performed under a project license (license number 04/2018) granted by the Veterinäramt des Kantons Zürich, Switzerland, in compliance with the Swiss Animal Protection Act (TSchG) and the Swiss Animal Protection Ordinance (TSchV).
Cloning, expression and protein purification
The fusion protein IL2-XE114-TNF mut contains the antibody XE114 (31) fused to a mutated version of human TNFa (arginine to alanine mutation in the amino acid position 108 of the human TNF gene, corresponding to the position 32 in the soluble form) at the C-terminus by a 15-amino acid linker and to human IL2 at the N-terminus by a 12-amino acid linker (6) . The gene encoding for the XE114 antibody and the gene encoding human TNF and human IL2 were PCR amplified, PCR assembled, and cloned into the mammalian expression vector pcDNA3.1(+) (Invitrogen) by a NheI/NotI restriction site as described previously (6) .
The fusion proteins used in this study were expressed using transient gene expression in CHO cells as described previously (33, 34) and purified from the cell culture medium to homogeneity by Protein A (Sino Biological) chromatography. 
In vitro characterization
Affinity measurements
Affinity measurements were performed by surface plasmon resonance using BIAcore X100 (BIAcore, GE Healthcare) instrument using a biotinylated CAIX coated streptavidin chip.
Samples were injected as serial-dilutions, in a concentration range from 1mM to 62.5nM.
Regeneration of the chip was performed by HCl 10 mM.
In vitro biological activities
The biological activity of TNF was determined by incubation with mouse LM fibroblasts, in the presence of 2µg/mL actinomycin D (Sigma-Aldrich). In 96-well plates, cells (20'000 per well) were incubated in medium supplemented with actinomycin D and varying concentrations of recombinant human TNF or IL2-XE114-TNF mut . After 24 h at 37C, cell viability was determined with Cell Titer Aqueous One Solution (Promega). Results were expressed as the percentage of cell viability compared to cells treated with actinomycin D only.
The biological activity of IL2 was determined by its ability to stimulate the proliferation of CTLL2 cells. Cells (25'000 per well) were seeded in 96-well plates in the culture medium supplemented with varying concentrations of the fusion proteins. After incubation at 37°C for 48 hours, cell proliferation was determined with Cell Titer Aqueous One Solution (Promega).
Results were expressed as the percentage of cell viability compared to untreated cells.
Flow cytometry
Antigen expression on SKRC52 cells was confirmed by flow cytometry. Cells were centrifuged and washed in cold FACS buffer (0.5% BSA, 2mM EDTA in PBS) and stained with IL2-XE114-TNF mut (final concentration 10µg/mL) and detected with rat anti-IL2 (eBioscience 14-7029-85) followed by staining with anti-rat AlexaFluor488 (Invitrogen A21208). IL2-KSF-TNF mut (specific for an irrelevant antigen) was used as negative control.
Immunofluorescence studies
Antigen expression was confirmed on ice-cold acetone fixed 8-µm cryostat sections of SKRC52 and CT26-CAIX stained with IL2-XE114-TNF mut and IL2-F8-TNF mut (final concentration 5µg/mL) and detected with rat anti-IL2 (eBioscience 14-7029-85) and anti-rat AlexaFluor488 (Invitrogen A21208). For vascular staining goat anti-CD31 (R&D AF3628) and anti-goat AlexaFluor594 (Invitrogen A11058) antibodies were used. IL2-KSF-TNF mut (specific for an irrelevant antigen) was used as negative control. Slides were mounted with fluorescent mounting medium and analysed with Axioskop2 mot plus microscope (Zeiss).
For ex vivo immunofluorescence analysis, mice were injected with 50-60µg IL2-XE114-TNF mut , IL2-F8-TNF mut or IL2-KSF-TNF mut and sacrificed 24 hours after injection. Organs were excised and embedded in cryo-embedding medium (Thermo Scientific) and cryostat section (10µm) were stained using the following antibodies: rat anti-IL2 (eBioscience 14-7029-85) and anti-rat AlexaFluor488 (Invitrogen A21208). For vascular staining goat anti-CD31 (R&D AF3628) and anti-goat AlexaFluor594 (Invitrogen A11058) antibodies were used.
Slides were mounted with fluorescent mounting medium and analysed with Axioskop2 mot plus microscope (Zeiss). 
Mice therapy studies
Pharmacokinetics analysis
Fusion protein concentrations in serum were assessed by AlphaLISA. Briefly, Streptavidin Donor Beads were coated with biotinylated antigen (CAIX for IL2-XE114-TNF mut or EDA for IL2-F8-TNF mut ). Acceptor Beads coated with an anti-TNF antibody were used for detection.
Statistical analysis
Data were analysed using Prism 7.0 (GraphPad Software, Inc.). Differences in tumor volume between therapeutic groups (until day 14, when n = 5) were evaluated with the two-way ANOVA followed by Bonferroni as post-test. P < 0.05 was considered statistically significant.
(*: P < 0.05, **: P < 0.01, ***: P < 0.001, ****: P < 0.0001).
Results
Figure 1A
depicts a schematic representation of a fully-human fusion protein (termed IL2-XE114-TNF mut ), featuring a sequential arrangement of IL2, a scFv fragment specific to CAIX (named XE114 (31)) and TNF [Supplementary Figure 1] . The protein arrangement is reminiscent of the one previously described for the murine fusion protein IL2-F8-TNF mut (6, 27) [ Supplementary Figure 2] , but here we used human payloads in order to facilitate clinical translational activities. The TNF moiety was de-potentiated by a single amino acid substitution (R108A), in order to achieve a similar cytokine activity for both IL2 and TNF moieties. ScFv(XE114) has previously been shown to recognize human CAIX with high affinity and kinetic stability (31, 35) . IL2-XE114-TNF mut was expressed in mammalian cells and could be purified on Protein A, since the scFv moiety featured a VH domain of the VH3 family (36, 37) . Figure 1G ]. IL2-XE114-TNF mut bound to SKRC52 renal cell carcinoma cell lines more intensely than IL2-KSF-TNF mut [ Figure   1H ], which was specific to hen egg lysozyme and was chosen as a negative control of irrelevant specificity in the mouse (38) [Supplementary Figure 3] . A multi-step denaturation profile was observed by differential scanning fluorimetry, with a first transition at 49.5 o C [ Figure 1J ].
The tumor-homing properties of IL2-XE114-TNF mut were first studied in nude mice, bearing subcutaneously-grafted human SKRC52 renal cell carcinomas [Figure 2 ]. Organs were examined 24 hours after intravenous administration of 60 µg of fusion protein, using an immunofluorescence procedure for the detection of the IL2 moiety. A homogenous antigen expression pattern was observed in an in vitro analysis of tumor sections. However, ex vivo, IL2-XE114-TNF mut mainly localized to perivascular tumor cells and failed to homogenously stain the CAIX-positive tumor mass. Similar targeting behaviors have previously been reported for other antibody products, directed against cell surface tumor antigens (31, 39) . No detectable antibody uptake could be seen in relevant normal organs [Figure 2] . By contrast, no tumor staining and no tumor uptake could be observed for the IL2-KSF-TNF mut negative control protein [ Figure 2B ].
In order to get a finer characterization of the tumor-targeting properties of our products, we compared IL2-XE114-TNF mut and IL2-F8-TNF mut (an analogue specific to the alternativelyspliced EDA domain of fibronectin) [Supplementary Figure 4 ] in mice bearing murine CT26 tumors, that had been stably-transfected for CAIX expression on the cell surface (30) . Both products exhibited a preferential accumulation at the tumor site, while IL2-KSF-TNF mut failed to localize to the neoplastic mass. However, the IL2-F8-TNF mut yielded a more homogenous pattern of tumor uptake compared to IL2-XE114-TNF mut , in spite of the fact that CAIX was strongly expressed on all tumor cells [ Figure 3 ].
We tested the therapeutic activity of IL2-XE114-TNF mut and IL2-F8-TNF mut in nude mice bearing CAIX-transfected CT26 tumors [Figure 4 ]. Since the human TNF moiety is only partly active in mice, we also studied the therapeutic activity of the mIL2-XE114-mTNF mut and mIL2-F8-mTNF mut analogues, bearing an attenuated version of murine TNF (6, 27) [ Supplementary Figure 2, 5] . A tumor-growth retardation was observed in this model, which lacked a functional set of T lymphocytes, but still retained natural killer (NK) cells [Figure 4 ].
All products caused a transient reduction in body weight at the dose used (30 µg), which was below the 10% threshold.
Finally, we compared the pharmacokinetic profiles of IL2-XE114-TNF mut and IL2-F8-TNF mut in Cynomolgus monkey, after a single intravenous administration (0.1mg/kg) [ Figure 5 ]. IL2-F8-TNF mut showed a biphasic clearance profile, with a rapid loss of ~ 2/3 of the protein from circulation, followed by a slower elimination phase. By contrast, IL2-XE114-TNF mut exhibited a slower clearance profile, with a half-life of approximately 2 hours. This pharmacokinetic profile is similar to the one that we have previously observed for other antibody-cytokine fusion proteins, which have progressed to advanced clinical trials (13, 18, 40, 41) .
Discussion
In this work we have described the generation, the in vitro characterization and the in vivo validation of a novel "potency-matched dual-cytokine antibody fusion protein" based on an anti-CAIX antibody fragment simultaneously fused to human IL2 and to a mutant version of human TNF. The product, named IL2-XE114-TNF mut , could be expressed in mammalian cells and purified to homogeneity. The fusion protein was able to recognize CAIX both in vitro and in vivo, when tested on a human renal cell carcinoma cell line (SKRC52, which naturally express the antigen) and in a murine colon carcinoma cell line (CT26-CAIX, which had been transfected with the human antigen).
We have previously reported that the intralesional administration of two immunocytokine products (L19-IL2 and L19-TNF) was able to induce cancer remission both in mouse models of cancer (24) and in patients with stage IIIB/C melanoma (22) . However, from an industrial prospective, the development of combination products may cause a duplication of activities and costs. By contrast, the opportunity of incorporate two cytokine payloads into the same antibody moiety may facilitate industrial development.
IL2-and TNF-based products have shown to be synergistically active against various type of malignancies (4, 6, 8, (22) (23) (24) (25) 27, 42) by two distinct complementary mechanism of actions. On one hand, TNF is capable of inducing hemorrhagic necrosis and apoptosis of the tumor endothelial cells and also of cancer cells (4, 6, 25, 43, 44) . On the other end, IL2 is able to promote a selective boosting of T cell and NK cell activity against cancer cells (6, 24, 26, 45) .
The therapeutic activity of IL2-XE114-TNF mut was evaluated in immunocompromised mice bearing human CAIX-transfected CT26 murine tumors. This mouse model, which lacked a functional set of T lymphocytes, but still retained NK cells, was chosen in order to avoid an immune response against the transfected human antigen. This may explain the reason why only an initial tumor growth inhibition was observed. We had previously reported that depletion studies in immunocompetent mice treated with IL2-F8-TNF mut revealed a prominent role of CD4+ and CD8+ T cells in the cancer remission process (6) .
Antibodies against cell surface antigens can recognize their cognate antigen with exquisite specificity, but often their penetration into solid malignancies can be suboptimal as a result of a slow extravasation rate due to their relatively large size (39, 46) . Indeed, IL2-XE114-TNF mut was found to preferentially localize to perivascular cells in vivo. Similar findings had been reported for antibodies specific to HER2 (39) . Interestingly, it has been shown that a small molecule against CAIX could penetrate CAIX-positive tumors more efficiently compared to an antibody against the same target (31) .
In spite of a suboptimal penetration in neoplastic lesions, IL2-XE114-TNF mut revealed an acceptable clearance profile, with a half-life of approximately 2 hours in monkeys, which was more favorable compared to the one of IL2-F8-TNF mut . This pharmacokinetic profile is comparable to the one previously observed for other cytokine-fusion proteins based on antibody-fragments (40, 47) . By contrast, IL2-F8-TNF mut exhibited a rapid clearance from circulation already at early time-points, possibly indicating a trapping of the F8 antibody in the liver, which was already observed for other F8-based immunocytokines (48) .
Renal cell carcinoma (RCC) represents a rare condition that account for approx. 2% of cancer deaths worldwide (49) . The most prominent subtype of RCC (about 70%) is clear cell (ccRCC) (50) . In most cases (70%) the tumor is confined to the kidney, but it may disseminate to regional lymph nodes and to visceral organs (50) . Surgical resection is the primary treatment option for stage I-III RCC, but postsurgical recurrence is observed with a 5-year relapse rate of 30-40% in patients with stage II or III RCC (51) . In the event of recurrence patients are typically treated with conventional chemotherapy (e.g. sunitinib), high dose IL2 or immune-checkpoint inhibitors (e.g. nivolumab and ipilimumab) (52, 53) . A phase III clinical trials in patients with advanced renal-cell carcinoma showed that the combination of nivolumab and ipilimumab could increase the overall survival compared to sunitinib alone (53) . However, this efficacy was observed only in a small portion of patients, for this reason novel therapeutics for the treatment of RCC may be required.
CAIX is strongly expressed in the majority of ccRCC. The antigen has been extensively validated as a target for ccRCC in preclinical studies and several antibodies against this antigen have been developed by our group and others (54, 55) . An humanized monoclonal antibody, named G250 (56) has been used to validate CAIX as a cancer target by nuclear medicine in clinical studies (50, 57) . The XE114 antibody fragment used in this study is a fully-human highaffinity antibody (31) , which may be considered for clinical development of CAIX-targeted based therapeutics.
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The product presented in this study (IL2-XE114-TNF mut ) was able to target CAIX in tumor bearing mice and showed a therapeutic effect in immunocompromised animals. Moreover, the favorable pharmacokinetic profile in monkey provide a rational for future clinical investigation. The targeted delivery of cytokine payloads to cell surface antigens may represent a valid alternative to the anchoring of pro-inflammatory payloads to the tumor extracellular matrix. To a certain extent, an immunocytokine able to selectively localize to tumor cell membrane may represent a functional equivalent to a "bispecific antibody" and may be capable of cross-link a tumor cell with a leukocyte (e.g. NK cell, T cell), which displays the cognate cytokine receptor on its surface. . For therapy experiments n = 5 mice/group. n = 4 for group IL2-XE114-TNF mut from day 15. n = 4 for groups mIL2-XE114-mTNF mut and mIL2-F8-mTNF mut from day 19. n = 3 for group mIL2-F8-mTNF mut from day 20.
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